Literature DB >> 10180747

Reassessing the relevance of pharmacoeconomic analyses in formulary decisions.

J A Johnson1, E Friesen.   

Abstract

Mesh:

Year:  1998        PMID: 10180747     DOI: 10.2165/00019053-199813050-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  19 in total

1.  Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions.

Authors:  R J Lipsy
Journal:  Pharmacoeconomics       Date:  1992-04       Impact factor: 4.981

2.  On squeezing balloons. Cost control fails again.

Authors:  S A Schroeder; J C Cantor
Journal:  N Engl J Med       Date:  1991-10-10       Impact factor: 91.245

3.  Rating the quality of evidence for clinical practice guidelines.

Authors:  D C Hadorn; D Baker; J S Hodges; N Hicks
Journal:  J Clin Epidemiol       Date:  1996-07       Impact factor: 6.437

4.  Canada's new guidelines for the economic evaluation of pharmaceuticals.

Authors:  D Menon; F Schubert; G W Torrance
Journal:  Med Care       Date:  1996-12       Impact factor: 2.983

Review 5.  Economic evaluation of pharmaceuticals. Frankenstein's monster or vampire of trials?

Authors:  B O'Brien
Journal:  Med Care       Date:  1996-12       Impact factor: 2.983

Review 6.  Sensitivity analysis in economic evaluation: a review of published studies.

Authors:  A Briggs; M Sculpher
Journal:  Health Econ       Date:  1995 Sep-Oct       Impact factor: 3.046

7.  Report from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals: Canada.

Authors: 
Journal:  Int J Technol Assess Health Care       Date:  1995       Impact factor: 2.188

8.  In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care.

Authors:  B J O'Brien; M F Drummond; R J Labelle; A Willan
Journal:  Med Care       Date:  1994-02       Impact factor: 2.983

9.  Effects of a limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia.

Authors:  S B Soumerai; T J McLaughlin; D Ross-Degnan; C S Casteris; P Bollini
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245

10.  Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes.

Authors:  S B Soumerai; D Ross-Degnan; J Avorn; T j McLaughlin; I Choodnovskiy
Journal:  N Engl J Med       Date:  1991-10-10       Impact factor: 91.245

View more
  4 in total

1.  Pharmacy benefit management: enhancing the applicability of pharmacoeconomics for optimal decision making.

Authors:  C Daniel Mullins; Junling Wang
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 2.  The effect of managed care on prescription drug costs and benefits.

Authors:  A Lyles; F B Palumbo
Journal:  Pharmacoeconomics       Date:  1999-02       Impact factor: 4.981

3.  A Systematic Review on the Extent and Quality of Pharmacoeconomic Publications in Egypt.

Authors:  Samar Farid; Mahmoud Elmahdawy; Darin Baines
Journal:  Clin Drug Investig       Date:  2019-02       Impact factor: 2.859

4.  Reconciling decision models with the real world. An application to anaemia of renal failure.

Authors:  Y C Shih; T L Kauf
Journal:  Pharmacoeconomics       Date:  1999-05       Impact factor: 4.981

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.